Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
FATE
#3071
Fate Therapeutics, Inc.
1.4
8
+2.07%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+2.07%
Monthly Change
+12.12%
6 month change
+28.70%
Year Change
+39.62%
Previous Close
1.4
5
Open
1.4
8
Bid
Ask
Low
1.4
8
High
1.4
8
Volume
50
Markets
US Stock Market
Healthcare
FATE
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Dividends per share
—
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
—
News
Baird reiterates Fate Therapeutics stock rating on trial progress
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics earnings beat, revenue topped estimates
Fate Therapeutics reports positive lupus treatment data at ASH meeting
Fate Therapeutics earnings beat by $0.03, revenue topped estimates
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Incyte (INCY) Tops Q3 Earnings and Revenue Estimates
Fate Therapeutics at Cantor Global Healthcare Conference: CAR T Cell Advances
Leerink Partners lowers Fate Therapeutics stock price target to $7 on iPSC CAR’iT pivot
Fate Therapeutics: Recent Update Met With Selling, But Positives Exist